stockmarketproxy
/
NUVLNasdaq SEC EDGAR

Nuvalent, Inc.

Pharmaceutical Preparations·CAMBRIDGE, MA·FY end 12/31·CIK 1861560
OverviewFinancialsCompensationGovernanceInsidersFilings

Financials

5-year history · USD
MetricFY 2025FY 2024FY 2023FY 2022FY 2021Trend
Revenue——————
Gross Profit——————
Operating Income-$414.3M-$280.4M-$149.5M-$86.1M-$45.8M
Net Income-$425.4M-$260.8M-$126.2M-$81.9M-$46.3M
Operating CF-$275.2M-$185.1M-$99.7M-$65.0M-$40.0M
Capex——————
Free Cash Flow——————
Buybacks——————
Dividends——————
Gross Margin——————
Operating Margin——————
Net Margin——————
FCF Margin——————
R&D / Revenue——————
Effective Tax-0.1%-0.3%———
Debt / Equity——————
Buybacks / FCF——————

Peer comparison

Pharmaceutical Preparations · 5 peers
CEO Pay Ratio
NUVL
21:1
ROIV
518:1
AXSM
23:1
COGT
95:1
PFE
277:1
ABT
166:1
CEO total comp
NUVL
—
ROIV
$163M
AXSM
$34M
COGT
$28M
PFE
$28M
ABT
$24M
Net Margin
NUVL
—
ROIV
-592.0%
AXSM
-28.7%
COGT
—
PFE
12.4%
ABT
14.7%